After the great success of the first edition of the ACT Summit, which was held in Dubai last May, Novo Nordisk Qatar, in cooperation with Ibn Sina Medical Company (a subsidiary of Aamal Company), hosted the second edition of the ACT (Advancing Cardio-Metabolic Treatment) Summit in Doha on October 17 and 18. 2025. The two-day scientific summit brought together more than 350 healthcare experts specializing in the treatment of obesity and diabetes from more than a dozen countries, including Qatar, the Gulf states, Pakistan, Iraq and Kazakhstan. Discussions focused on the pressing issues of heart and kidney complications resulting from obesity and type 2 diabetes, highlighting the importance of a multidisciplinary approach to improving patient outcomes, promoting long-term weight loss and controlling blood sugar levels, as well as exploring the role that semaglutide treatments can play in combating these diseases.
A group of experts in the field of healthcare from Qatar and around the world, including Germany, the United States of America, Canada, and Italy, participated in the summit, where they presented the latest insights into modern therapeutic innovations and the importance of continuity of care for obesity patients from adolescence to adulthood, in addition to discussing new models of integrated care. Novo Nordisk has more than 100 years of global leadership in chronic disease treatment and 25 years of obesity research. The company recently launched Semaglutide 2.4 mg in Qatar in cooperation with Ibn Sina Medical Company, in an important step towards recognizing obesity as a serious chronic disease that requires treatment. Manvendra Singh (MAN), Managing Director, Novo Nordisk Qatar, said: “The ACT Summit underscores Novo Nordisk’s commitment to supporting advanced medical education and enabling healthcare professionals to access the latest scientific knowledge. Hosting this event in Doha reflects Qatar’s growing role as a regional center for medical excellence and scientific cooperation. As rates of obesity, diabetes and heart disease continue to rise in Qatar and the region, the ACT Summit represents an essential platform to strengthen the healthcare system and improve patient outcomes through innovative, science-based solutions.” Mr. Rashid Al Mansouri, CEO of Aamal Company Q.P.S.C., added: “I am pleased to participate in this important conference and to speak in front of a distinguished group of specialists in the medical sector. We are proud that Ibn Sina Medical Company, a subsidiary of Aamal Company, continues its partnership with leading international companies such as Novo Nordisk. The second summit (ACT2) demonstrates our joint commitment to developing medical education and supporting Qatar’s vision of improving public health indicators.”
During the two-day summit, attendees participated in interactive plenary sessions and practical lessons based on analysis of clinical cases, in addition to workshops that addressed the interrelationship between obesity, diabetes, and heart and kidney complications. The summit concluded with a joint call to action, calling for strengthening integrated care approaches and accelerating collaborative solutions to reduce the regional burden of cardio-metabolic diseases.
